Meeting
2019 ASCO Annual Meeting
Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact.
Authors
Michael Fusco
Moffitt Cancer Center, Tampa, FL
Michael Fusco , Robert J Macaulay , Peter A. J. Forsyth , Christine Marie Walko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2058)
DOI
10.1200/JCO.2019.37.15_suppl.2058
Abstract #
2058
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
First Author: Arielle Lutterman Heeke
Poster
2013 ASCO Annual Meeting
Biomarker analysis of glioblastoma and potential implications for therapy.
First Author: Joanne Xiu
Poster
2024 ASCO Annual Meeting
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).
First Author: Celine Yeh
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas